BioPharma Dive August 26, 2024
The venture firm managing partner is behind Borealis Biosciences, which launched last week with a deal in place giving Novartis an option to acquire two of its research programs.
Private investment in young biotechnology companies has appeared to stabilize after an up-and-down past few years, with funding totals from the first half of 2024 roughly matching the pre-pandemic pace.
But the sector is not booming like it was in 2021 and 2022. Initial public offerings remain challenging, pushing more private companies to pursue, or at least consider, deals with pharmaceutical companies. Those large drugmakers are now handing over less cash in licensing agreements than they did previously, however.
Firms such as Versant Ventures are getting creative, including by turning to...
Today's Sponsors
Today's Sponsor